Faron Pharmaceuticals doses first patient in Phase 1/2 BLAZE trial of bexmarilimab plus Bristol Myers’ Opdivo in PD-1-resistant solid tumors

• Faron Pharmaceuticals Oyj dosed the first patient in the Phase 1/2 BLAZE investigator-initiated trial of bexmarilimab with nivolumab.
• Results have not been presented; the trial is designed to generate future safety and anti-tumor activity data in anti-PD-1-resistant NSCLC and melanoma.
• The study targets patients whose disease progressed after prior immunotherapy, testing whether the combination can restore sensitivity to checkpoint inhibition.
• The regimen uses an initial bexmarilimab run-in before combination dosing, supporting Faron’s strategy to expand into PD-1 combination treatment settings.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on October 01, 2026, and is solely responsible for the information contained therein.